Myasthenia Gravis
Disease, Diagnosis and Management
- 1st Edition - December 19, 2025
- Latest edition
- Editors: Bhupendra G. Prajapati, Devesh U. Kapoor, Jaimin R. Shah
- Language: English
Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoim… Read more
Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoimmune disease affecting the neuromuscular junction. With contributions from global experts, this book addresses the increasing prevalence of Myasthenia Gravis, reflecting the latest in diagnostic techniques and novel therapies such as complement inhibitors and FcRn antagonists. It aims to support healthcare professionals in delivering optimal care through evidence-based insights and patient-centered approaches. The book is divided into several chapters, beginning with an overview of the pathogenesis and immunoregulatory defects in Myasthenia Gravis. Subsequent chapters cover diagnostic methods, non-immunosuppressive treatments, and biological therapies targeting the immune system. Key topics include the role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) in severe exacerbations, thymectomy, molecular mechanisms, and the potential of hematopoietic stem cell transplants. The book also delves into precision medicine, AI applications, clinical trial considerations, and novel therapeutics like anti-FcRn antibodies. Management strategies for ocular Myasthenia Gravis, and a holistic view of living with the disease are also discussed. Myasthenia Gravis: Disease, Diagnosis and Management is invaluable for healthcare providers, physicians, immunologists, ophthalmologists, rheumatologists, physical therapists, pharmacists, and translators. It offers a modern guide to understanding and managing Myasthenia Gravis, integrating clinical expertise with the latest research to improve patient outcomes.
- Explores pathogenesis, diagnosis, and treatment options for Myasthenia Gravis, providing a complete understanding of the disease
- Highlights cutting-edge therapies like complement inhibitors and FcRn antagonists for improved patient outcomes
- Ensures authoritative and up-to-date information contributed by global experts
- Offers evidence-based strategies for healthcare professionals to optimize Myasthenia Gravis management
- Integrates clinical expertise with patient-centered care for a well-rounded perspective on disease management
Researchers and clinicians interested in the mechanisms and treatment of Myasthenia gravis
1. Introduction to Myasthenia Gravis and Ocular Myasthenia Gravis
2. Diagnosis of Myasthenia Gravis
3. Non-immunosuppressive Treatment of Myasthenia Gravis
4. Biologicals -Monoclonal Antibodies Targeting Immune System for Myasthenia Gravis Treatment
5. Novel Immunotherapies for Myasthenia Gravis
6. Management of Myasthenia Gravis in Severe Exacerbation
7. Role of Thymectomy in Myasthenia Gravis
8. Molecular Mechanisms of Myasthenia Gravis
9. Management of Myasthenia Gravis with Hematopoietic Stem Cell Transplant
10. Precision Medicine in Myasthenia Gravis
11. Application of AI in Management of Myasthenia Gravis
12. Clinical Trial Considerations in Myasthenia Gravis
13. Anti-FcRn Antibodies Based Novel Therapeutics
14. Management of Ocular Myasthenia Gravis
15. Living with Myasthenia Gravis and Future Perspective
2. Diagnosis of Myasthenia Gravis
3. Non-immunosuppressive Treatment of Myasthenia Gravis
4. Biologicals -Monoclonal Antibodies Targeting Immune System for Myasthenia Gravis Treatment
5. Novel Immunotherapies for Myasthenia Gravis
6. Management of Myasthenia Gravis in Severe Exacerbation
7. Role of Thymectomy in Myasthenia Gravis
8. Molecular Mechanisms of Myasthenia Gravis
9. Management of Myasthenia Gravis with Hematopoietic Stem Cell Transplant
10. Precision Medicine in Myasthenia Gravis
11. Application of AI in Management of Myasthenia Gravis
12. Clinical Trial Considerations in Myasthenia Gravis
13. Anti-FcRn Antibodies Based Novel Therapeutics
14. Management of Ocular Myasthenia Gravis
15. Living with Myasthenia Gravis and Future Perspective
- Edition: 1
- Latest edition
- Published: December 19, 2025
- Language: English
BP
Bhupendra G. Prajapati
Dr. Bhupendra Gopalbhai Prajapati is a Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India. He is also acting as Adjunct Professor at Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, Thailand. With over 22 years of experience in academia, research, and industry, he specializes in lipid-based formulations, nano/microparticulate drug delivery, and bioavailability enhancement. A recipient of several prestigious awards including the AICTE Young Teacher Award and Ganpat University's Staff Excellence honors, Dr. Prajapati has published over 350 research/review papers, and has contributed to more than 170 book chapters. He actively mentors Ph.D. and PG scholars and serves as editor or section editor for several international publications in pharmaceutical sciences.
Affiliations and expertise
Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara, Gujarat, IndiaDK
Devesh U. Kapoor
Dr. Devesh U. Kapoor is currently serving as a Professor at Dr. Dayaram Patel Pharmacy College, Bardoli, District Surat, Gujarat. The institution is funded by the Directorate of Technical Education (DTE), Government of Gujarat, and is affiliated with Gujarat Technological University. Dr. Kapoor is alumnus of University of Rajasthan, Jaipur and Department of Pharmaceutics, BN College of Pharmacy, Rajasthan University of Health Sciences, Jaipur, Rajasthan, India. He was awarded a Ph.D. in Pharmaceutical Sciences in 2013. Dr. Kapoor serves as an Associate Editor for Naunyn-Schmiedebergs Archives of Pharmacology (Springer Nature), Future Journal of Pharmaceutical sciences (Springer Open), Scientific Reports (Springer Nature), Recent Advances in Drug Delivery & Formulation (Bentham Science) and PLOS One, Frontiers in Medicine - Precision Medicine and Frontiers in surgery. He is a Consulting Editor for Cytotechnology (Springer). He has peer-reviewed manuscripts for approximately 135 prestigious journals from publishers such as Elsevier, MDPI, Springer, Wiley, Frontiers, Dove Press, Bentham Science, Taylor & Francis, Wolters Kluwer (Medknow), and De Gruyter. With over 20 years of experience in teaching and academic administration, Dr. Kapoor has published more than 175 research and review articles in reputed national and international journals. In addition to his editorial responsibilities, Dr. Kapoor is currently editing 18 international books with publishers such as Elsevier, Springer, Wiley, Taylor & Francis, CRC Press, RSC. He has also contributed 50 book chapters published by renowned publishers including Elsevier, Bentham Science, MDPI, Springer, RSC and Wiley. He is currently supervising four Ph.D. students, focusing on nanodrug delivery systems and modified drug release from Gujarat Technological University, Ahemdabad. He fetched research and event organization grants from various government bodies including the Gujarat Council of Science & Technology (GUJCOST), Gujarat State Biotechnology Mission (GSBTM), and AICTE-ATAL for national seminars and faculty development programs. Dr. Kapoor holds 8 design patents and has delivered over 20 expert talks. He is frequently invited to speak at scientific sessions in national conferences, seminars, and workshops.
Affiliations and expertise
Professor, Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, IndiaJS
Jaimin R. Shah
Dr. Jaimin R. Shah is the Founder, President, and CEO of Upsilon Innovations, based in San Diego, California, and a researcher at the University of California, San Diego. With over 14 years of experience in academia and industry, he has been a key member of multiple pharmaceutical startups and has worked on over 80 product development projects. Dr. Shah specializes in innovative drug delivery technologies, focusing on cancer, autoimmune diseases, rare diseases, and regenerative medicine. He has published numerous research papers, co-authored book chapters, and holds multiple patents. His expertise spans various dosage forms, including transdermal, topical, lipid-based systems, ophthalmics, and injectables. Dr. Shah holds a B.Pharm from Gujarat University, an M.S. in Pharmaceutics from Long Island University, and a Ph.D. in Materials Science and Engineering from UC San Diego. He is an active member of AAPS, ACS, AACR, and RSC.
Affiliations and expertise
Founder, President, CEO, Upsilon Innovations, San Diego, CA, USA; Researcher, Department of Chemistry and Biochemistry, School of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA